Cerebrolysin vs Semax: Comparing Neurotrophic Pharmacology and Clinical Evidence

Cerebrolysin and Semax appear together on most nootropic-peptide comparison lists, but a close read of the primary literature shows they are far more different than they are similar. They share a framing — neurotrophic-mediated cognitive and neuroprotective effects — but the compounds themselves, the routes of administration, the level of clinical evidence, and the regulatory contexts differ substantially. This article walks through the mechanism, the strongest trials, and what each compound is and is not.

Composition: a mixture vs a single peptide

Cerebrolysin is a standardised preparation of low molecular weight peptides and free amino acids derived from porcine brain tissue. It is administered intravenously or intramuscularly. Its biological identity is the neurotrophic-mimetic activity of the mixture rather than any single defined fragment. Manufacturing yields a reproducible profile of activity, not a single chemical structure.

Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence (Met-Glu-His-Phe-Pro-Gly-Pro). It is administered intranasally and crosses the blood-brain barrier via the nasal mucosa pathway. It is a single defined molecule with a single sequence.

This compositional distinction matters because it shapes the regulatory and trial-replication landscape. A single defined molecule is easier to standardise across labs and trials; a defined-activity mixture is harder to replicate exactly outside the original manufacturer's process, which limits cross-trial comparability.

Mechanism overlap on the BDNF axis

Both compounds are studied for effects on brain-derived neurotrophic factor (BDNF) and related neurotrophins, but they enter the BDNF story from different angles.

Semax's BDNF mechanism is the more directly characterised. Dolotov and colleagues (2006, Brain Res) ⁴ demonstrated that intranasal Semax administration produces measurable upregulation of both BDNF and TrkB (the BDNF receptor) in the rat hippocampus. Shadrina and colleagues (2010, J Mol Neurosci) ⁵ extended this with temporal-dynamics data across hippocampus, frontal cortex, and retina — both BDNF and NGF (nerve growth factor) showed coordinated transcript changes. Agapova and colleagues (2007, Neurosci Lett) ⁶ independently replicated the neurotrophin-gene-expression response. The Semax-BDNF story is supported by three independent rat studies that converge on the same mechanism.

Cerebrolysin's BDNF mechanism is documented at a different level. Its peptide fragments cross the blood-brain barrier and mimic the activity of endogenous neurotrophic factors — BDNF, GDNF, NGF, and CNTF — but the specific active fragments are characterised by their downstream activity rather than by their identity. The mechanism is real and reproducible at the biological-effect level; it is not as cleanly traced at the molecular level because the active mixture is not a single molecule.

The shared upstream signal is BDNF. The broader BDNF-neuroprotection literature ⁷ supports BDNF as a credible drug-discovery target across depression, neurodegeneration, and cognitive aging. Both compounds plug into this axis.

Clinical evidence: trial-level vs mechanism-level

The clinical evidence bases diverge sharply.

Cerebrolysin: three pivotal trials

CASTA (Heiss 2012, Stroke) ¹ randomised ~1,070 patients with acute ischemic stroke at Asian centres to Cerebrolysin 30 mL IV daily for 10 days plus standard care vs placebo plus standard care. The primary endpoint — modified Rankin Scale (mRS) at day 90 — did not show a statistically significant difference between groups in the overall population. A pre-specified subgroup analysis of patients with NIHSS ≥12 at baseline suggested benefit, but the overall negative result is the methodologically defensible headline. CASTA's size and rigour make it the most credible negative-outcome Cerebrolysin trial.

CARS (Muresanu 2016, Stroke) ² was a placebo-controlled multicentre RCT focused on motor-function recovery after ischemic stroke. Cerebrolysin demonstrated statistically significant improvement on the Action Research Arm Test (ARAT) at day 90, the primary endpoint. CARS is the more frequently cited positive result and is the basis for current European stroke-recovery clinical use. The interpretive challenge: CASTA was negative on overall mRS and CARS was positive on motor-specific ARAT, so the evidence base supports motor recovery more cleanly than overall functional recovery.

Alvarez 2011 (Eur J Neurol) ³ enrolled patients with moderate-to-moderately-severe Alzheimer's disease and tested three Cerebrolysin dosages versus placebo over 6 months. Cerebrolysin produced statistically significant dose-dependent improvement on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and on the CIBIC+ global change measure. This trial, alongside earlier Cerebrolysin Alzheimer work, supports the European clinical use in vascular and Alzheimer-type dementia.

Semax: mechanism studies + smaller human trials

Semax's evidence base is dominated by rat-model mechanism work (the three BDNF/NGF transcript studies cited above) and smaller Russian-tradition human studies for cognitive and neuroprotective indications. Phase 3-equivalent Western replication is not yet present in the published literature. The mechanism story is well-supported; the human-translation story is at an earlier stage of independent replication.

Routes, dosing windows, and practical research considerations

| | Cerebrolysin | Semax | |---|---|---| | Route | IV (slow infusion) or IM | Intranasal | | Course | 10–21 days IV/IM courses; maintenance 5–10 mL IM several times weekly | Daily intranasal courses, typically 2–4 weeks | | Onset of effect | Cumulative across course (no acute single-dose effect) | Acute behavioural effects reported within hours; durable transcript changes over days | | Trial-level outcome data | Three pivotal trials (CASTA, CARS, Alvarez 2011) | None of equivalent size in Western literature | | Mechanism characterisation | Activity-level (peptide mixture) | Molecule-level (single heptapeptide) |

What is settled vs. exploratory

Settled for Cerebrolysin: motor-recovery benefit after ischemic stroke (CARS); cognitive improvement in moderate-to-moderately-severe Alzheimer's (Alvarez 2011); a defined neurotrophic-mimetic mechanism. The negative overall result in CASTA is also settled — and the appropriate interpretation is that overall mRS recovery is not reliably improved, while motor-specific endpoints are.

Settled for Semax: BDNF and TrkB upregulation in rat hippocampus following intranasal administration; coordinated neurotrophin response across multiple brain regions; activating cognitive profile in rodent behavioural paradigms.

Exploratory for both: combinatorial protocols, head-to-head efficacy comparison (no published direct comparison trial exists), long-term safety beyond the trial windows reported, and translation to chronic neurodegenerative-disease prevention rather than acute injury recovery.

Picking between the two for a research protocol

The choice depends on the research question.

For acute or subacute stroke motor-recovery research: Cerebrolysin has the direct trial evidence (CARS). Semax does not have equivalent stroke-recovery trial data.

For mechanism-level BDNF/TrkB pharmacology research: Semax has the cleaner traceable mechanism in the published literature. Cerebrolysin's mechanism is biologically real but the active-fragment identification is incomplete.

For dementia or cognitive-aging research: Cerebrolysin has the stronger Phase 3-level evidence (Alvarez 2011). Semax has parallel but smaller human studies.

For acute cognitive-task performance research (a common use case in nootropic protocols): Semax's intranasal route and faster onset profile fit better than Cerebrolysin's multi-day IV/IM courses.

For a stack-vs-monotherapy comparison: no published trial exists. This is a research-question opportunity, not an answered question.

For the long-form Cerebrolysin treatment, see the Cerebrolysin neurotrophic research article. For Semax mechanism details, see the Semax and Selank BDNF article.